Medicina y salud
Disciplina temática
Royal Adelaide Hospital
Adelaida, AustraliaPublicaciones en colaboración con investigadores/as de Royal Adelaide Hospital (12)
2024
-
Clinical relevance of intracranial hemorrhage after thrombectomy versus medical management for large core infarct: a secondary analysis of the SELECT2 randomized trial
Journal of NeuroInterventional Surgery, pp. 1-8
-
Endovascular Thrombectomy for Large Ischemic Stroke Across Ischemic Injury and Penumbra Profiles
JAMA, Vol. 331, Núm. 9, pp. 750-763
2022
2021
-
Elective Cancer Surgery in COVID-19-Free Surgical Pathways during the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study
Journal of Clinical Oncology, Vol. 39, Núm. 1, pp. 66-78
-
Global impact of COVID-19 on stroke care
International Journal of Stroke, Vol. 16, Núm. 5, pp. 573-584
-
Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection
BJS Open
-
Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: The COVIDSurg mortality score
British Journal of Surgery, Vol. 19, Núm. 4
-
Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic
Colorectal Disease, Vol. 23, Núm. 3, pp. 732-749
-
Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic
British Journal of Surgery, Vol. 108, Núm. 1, pp. 88-96
2020
-
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk
Journal of Hematology and Oncology, Vol. 13, Núm. 1
2018
-
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR
Haematologica, Vol. 103, Núm. 12, pp. 2079-2087
2013
-
Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: A prospective randomized trial from the lymphoma working party of the European Group for Blood and Marrow Transplantation
Journal of Clinical Oncology, Vol. 31, Núm. 13, pp. 1624-1630